Can a higher dose of a common drug tame hepatitis c?
NCT ID NCT00200343
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether higher doses of ursodeoxycholic acid (UDCA) could better lower liver enzymes in 596 adults with chronic hepatitis C. Participants received 150, 600, or 900 mg of UDCA daily for 24 weeks. The main goal was to see if the higher doses were more effective and safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ursodeoxycholic acid (UDCA)
- What this could lead to
- If successful, higher doses of UDCA could help control liver inflammation in people with chronic hepatitis C.
- What could go wrong
- This trial is completed and focused on liver enzyme changes, not on curing the infection. Results may not lead to a new standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Gastroenterology, University of Tokyo
Hongo, Bunkyo-ku, Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a cholesterol drug and a bile acid pill help reverse liver scarring?
- Massive study aims to map hepatitis c elimination in pakistan
- Can a blood pressure drug reverse liver damage in hepatitis c?
- New hepatitis c drug combo shows promise in early trial
- New study tests faster hepatitis c detection for drug users
- New hope: hepatitis c drugs after liver cancer treatment